Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib in AD post-Dupilumab
NCT05602207Phase 4Completed
- Sponsor
- Innovaderm Research
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of abrocitinib in atopic dermatitis (AD), sponsored by Innovaderm Research. Primary endpoint: Eczema Area and Severity Index at 12 weeks. Started Nov 2022; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05602207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602207.